Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEpe Special Opp Regulatory News (ESO)

Share Price Information for Epe Special Opp (ESO)

Share Price is delayed by 15 minutes
Get Live Data
235.00    -2.00 (-0.84%)
Bid:
232.00
Ask:
238.00
Spread: 6.00 (2.586%)
Market Cap: £57.47m
ESO Live PriceLast checked at - London Stock Exchange

Intraday Epe Special Opp Share Chart

Portfolio Update

29 Mar 2018 07:00

RNS Number : 3283J
EPE Special Opportunities PLC
29 March 2018
Β 

EPE Special Opportunities plc

29 March 2018

Β 

This announcement contains inside information

Β 

EPE Special Opportunities plcPortfolio Update

EPE Special Opportunities plc ("ESO plc", or the "Company") announces that Pharmacy2U Limited ("P2U"), a company in which it has a minority investment via ESO Investments 1 LP ("ESO 1 LP"), has raised a further Β£40 million of new growth capital to support the rapid expansion of its online NHS repeat prescription service.

P2U is England's leading online NHS pharmacy and is the fastest growing pharmacy group in the country, with 25,000 new patient registrations in the last month alone and year-on-year growth in patient numbers of 178%.

As well as offering consumers increased choice and convenience, P2U's online prescription management service is highly beneficial for the healthcare economy, saving GPs an estimated six hours and 40 minutes a week on paperwork. It is estimated that managing repeat prescriptions online could save the NHS over Β£300 million per year on prescription costs.

The growth capital raise was led by G Square Capital, a European private equity firm focussed on the healthcare sector. In conjunction with the new investment, G Square Capital also acquired a majority of the share capital of P2U from existing shareholders and as a result is now the majority shareholder.

The new investment will allow P2U to invest further in technology infrastructure to support customer demand and remain at the forefront of innovation in digital pharmacy services. P2U's state-of-the-art, award winning dispensing facility in Leeds is already the largest and most technologically advanced in the United Kingdom, with the ability to dispense one million prescription items per month.

ESO 1 LP has realised 50% of its existing investment in P2U in the transaction, implying a 2.0x Money Multiple realised return. The transaction was completed at a premium to the holding value of P2U. The remaining 50% of ESO 1 LP's investment has been retained to benefit from the growth potential in P2U offered by the Β£40 million investment. This retained investment offers further upside in terms of Money Multiple returns to ESO 1 LP

The person responsible for releasing this information on behalf of the Company is Hilary Jones of R&H Fund Services (Jersey) Limited.

Β 

Enquiries:

Β 

EPIC Private Equity LLP

+44 (0) 207 269 8865

Alex Leslie

R&H Fund Services (Jersey) Limited

+44 (0) 1534 825 323

Hilary Jones

Cardew Group Limited

+44 (0) 207 930 0777

Richard Spiegelberg

Numis Securities Limited

+44 (0) 207 260 1000

Nominated Advisor:

Stuart Skinner / Hugh Jonathan

Corporate Broker:

Charles Farquhar

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
PFUDBGDXXBDBGII
Date   Source Headline
16th Oct 202510:15 amRNSAnnouncement of Ordinary and ZDP Share Buybacks
23rd Sep 20257:00 amRNSNet Asset Value(s)
9th Sep 20257:00 amRNSHalf-year Report
27th Aug 20257:00 amRNSPortfolio Update
8th Aug 20254:00 pmRNSUpdate on Share Buy Backs
25th Jul 20255:00 pmRNSHolding(s) in Company
24th Jul 20256:00 pmRNSInterest Payment on Unsecured Loan Notes
14th Jul 20251:00 pmRNSNet Asset Value(s)
10th Jul 20257:15 amRNSHolding(s) in Company
10th Jul 20257:00 amRNSTransaction in Own Shares
4th Jul 202510:00 amRNSInvestment
30th Jun 20257:00 amRNSChange of Nominated Adviser
27th Jun 20258:00 amRNSResults of Annual General Meeting
26th Jun 20257:00 amRNSTransaction in Own Shares
19th Jun 20257:30 amRNSTransaction in Own Shares
17th Jun 20251:00 pmRNSNet Asset Value(s)
13th Jun 20251:00 pmRNSProposed Extension of Unsecured Loan Notes
13th Jun 20257:00 amRNSTransaction in Own Shares
12th Jun 202511:57 amRNSTransaction in Own Shares
29th May 20255:30 pmRNSTransaction in Own Shares
28th May 20257:15 amRNSHolding(s) in Company
28th May 20257:00 amRNSTransaction in Own Shares
27th May 20255:30 pmRNSNotice of Annual General Meeting
27th May 20257:00 amRNSTransaction in Own Shares
23rd May 20257:00 amRNSTransaction in Own Shares
22nd May 20257:00 amRNSTransaction in Own Shares
21st May 20257:00 amRNSTransaction in Own Shares
16th May 20257:00 amRNSTransaction in Own Shares
15th May 20253:00 pmRNSNet Asset Value(s)
15th May 20257:15 amRNSHolding(s) in Company
15th May 20257:00 amRNSTransaction in Own Shares
6th May 20257:00 amRNSTransaction in Own Shares
2nd May 20257:15 amRNSAnnual Financial Report
2nd May 20257:00 amRNSTransaction in Own Shares
24th Apr 20257:00 amRNSTransaction in Own Shares
16th Apr 20257:00 amRNSTransaction in Own Shares
15th Apr 20257:00 amRNSNet Asset Value(s)
15th Apr 20257:00 amRNSTransaction in Own Shares
14th Apr 20257:20 amRNSTransaction in Own Shares
14th Apr 20257:10 amRNSVesting - Share Matching Scheme/PDMR Shareholdings
14th Apr 20257:00 amRNSDirector/PDMR Shareholding
11th Apr 20257:00 amRNSTransaction in Own Shares
9th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSTransaction in Own Shares
4th Apr 20257:00 amRNSTransaction in Own Shares
3rd Apr 20251:00 pmRNSAnnouncement of Share Buy Backs
26th Mar 20257:00 amRNSAnnual Financial Report
25th Feb 20251:00 pmRNSDirector/PDMR Shareholding
13th Feb 20257:00 amRNSTrading Statement
4th Feb 20257:00 amRNSInterest Payment on Unsecured Loan Notes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.